Neurolief

Neurolief is a medical technology company based in Netanya, Israel, founded in 2013. The company specializes in non-invasive brain neuromodulation therapies aimed at treating mental health and neurological disorders. Neurolief has developed the world's first multi-channel brain neuromodulation system, which targets major neural pathways involved in mood regulation and pain management. The flagship product, Relivion, is a digital therapeutics platform that provides clinically proven neuromodulation solutions for patients to use at home or in community settings. It is FDA-approved in the USA, CE-marked in Europe, and approved by Japan’s PMDA for migraine treatment. Neurolief is also pursuing regulatory approvals for the treatment of major depression. The company's innovative technology stimulates multiple brain regions simultaneously, offering potential relief for chronic conditions like migraine and depression. Neurolief's leadership team consists of experts in neuroscience and medical device commercialization. The company targets patients with chronic neurological disorders, healthcare providers, and partners in the pharmaceutical and medical device industries, including a strategic partnership with Sawai Pharmaceutical in Japan.

• Employees 28
• Founded 2014
• Annual Revenue $4500000